Cargando…
Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers
BACKGROUND AND OBJECTIVES: Entospletinib is a selective, reversible, adenosine triphosphate-competitive small-molecule spleen tyrosine kinase (SYK) inhibitor that blocks B cell receptor-mediated signaling and proliferation in B lymphocytes. This study evaluated the safety, pharmacokinetics, and phar...
Autores principales: | Ramanathan, Srini, Di Paolo, Julie A., Jin, Feng, Shao, Lixin, Sharma, Shringi, Robeson, Michelle, Kearney, Brian P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5250654/ https://www.ncbi.nlm.nih.gov/pubmed/27785737 http://dx.doi.org/10.1007/s40261-016-0476-x |
Ejemplares similares
-
Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib
por: Sender, Sina, et al.
Publicado: (2021) -
Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers
por: Wang, Shining, et al.
Publicado: (2022) -
Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics
por: Li, Junfeng, et al.
Publicado: (2015) -
Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization
por: Cao, G, et al.
Publicado: (2013) -
The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers
por: Umemura, Kazuo, et al.
Publicado: (2016)